Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Assets (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Assets over the past 10 years, most recently at $28.3 million for Q4 2023.

  • For Q4 2023, Assets fell 57.37% year-over-year to $28.3 million; the TTM value through Dec 2023 reached $28.3 million, down 57.37%, while the annual FY2023 figure was $28.3 million, 57.37% down from the prior year.
  • Assets for Q4 2023 was $28.3 million at Corbus Pharmaceuticals Holdings, down from $36.3 million in the prior quarter.
  • Over five years, Assets peaked at $140.1 million in Q1 2021 and troughed at $28.3 million in Q4 2023.
  • A 5-year average of $81.5 million and a median of $83.1 million in 2019 define the central range for Assets.
  • Biggest five-year swings in Assets: soared 114.93% in 2021 and later plummeted 57.37% in 2023.
  • Year by year, Assets stood at $49.1 million in 2019, then surged by 108.16% to $102.3 million in 2020, then increased by 5.31% to $107.7 million in 2021, then tumbled by 38.45% to $66.3 million in 2022, then plummeted by 57.37% to $28.3 million in 2023.
  • Business Quant data shows Assets for CRBP at $28.3 million in Q4 2023, $36.3 million in Q3 2023, and $43.7 million in Q2 2023.